AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure Inc (ATRC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Positive Cash Flow Amid Increased Expenses
Q2 2024 AtriCure Inc Earnings Call Transcript
No summary available.
AtriCure (NASDAQ: ATRC ) just reported results for the second quarter of 2024. AtriCure reported earnings per share of -17 cents. This met the analyst estimate for EPS of -17 cents. The company reported revenue of $116.27 million. This was 0.08% better than the analyst estimate for revenue of $116.18 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
AtriCure (ATRC) reports Q2 earnings in-line with non-GAAP EPS of -$0.17, revenue beats expectations at $116.3M (+15.3% Y/Y).
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results. “Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip franchises, as we continued to Jetzt den vollständigen Artikel lesen
AtriCure to present at Canaccord Genuity''s Global Growth Conference. Learn about their innovations in atrial fibrillation treatments and growth strategies. Live webcast available August 13, 2024, at 10:30 am EST.
No summary available.
AtriCure receives regulatory approval to sell AtriClip devices in China, based on clinical data showing safety and efficacy.
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake. In this case, I’ve chosen the arbitrary price level of $20. All of the shares discussed in this article are priced between $20 and $25. Each share is also projected to double in price over the next 12 to 18 months. Make no mistake about it, this is risky investing. However, at this price range we aren’t talking about penny stocks , so we have at least graduated above that level of risk. Make your own individual determination as it relates to the amount of risk you are willing to assume. As for industries, there’s a reasonably diverse offering of companies represented here. As expected, there are a few biotechnology firms that are well represented at the penny stock level. Let’s take a look at these companies to buy for growth and their stocks. AtriCure (ATRC) Source: Dmytro Zinkevych / Shutterstock.com AtriCure (NASDAQ: ATRC ) is a stock representing a manufacturer and seller of devices used in the surgical ablation of cardiac tissue and other ablation procedures.